Literature DB >> 19628114

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.

Thanh T Phan1, Khalid Abozguia, Ganesh Nallur Shivu, Gnanadevan Mahadevan, Ibrar Ahmed, Lynne Williams, Girish Dwivedi, Kiran Patel, Paul Steendijk, Houman Ashrafian, Anke Henning, Michael Frenneaux.   

Abstract

OBJECTIVES: We sought to evaluate the role of exercise-related changes in left ventricular (LV) relaxation and of LV contractile function and vasculoventricular coupling (VVC) in the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and to assess myocardial energetic status in these patients.
BACKGROUND: To date, no studies have investigated exercise-related changes in LV relaxation and VVC as well as in vivo myocardial energetic status in patients with HFpEF.
METHODS: We studied 37 patients with HFpEF and 20 control subjects. The VVC and time to peak LV filling (nTTPF, a measure of LV active relaxation) were assessed while patients were at rest and during exercise by the use of radionuclide ventriculography. Cardiac energetic status (creatine phosphate/adenosine triphosphate ratio) was assessed by the use of (31)P magnetic resonance spectroscopy at 3-T.
RESULTS: When patients were at rest, nTTPF and VVC were similar in patients with HFpEF and control subjects. The cardiac creatine phosphate/adenosine triphosphate ratio was reduced in patients with HFpEF versus control subjects (1.57 +/- 0.52 vs. 2.14 +/- 0.63; p = 0.003), indicating reduced energy reserves. Peak maximal oxygen uptake and the increase in heart rate during maximal exercise were lower in patients with HFpEF versus control subjects (19 +/- 4 ml/kg/min vs. 36 +/- 8 ml/kg/min, p < 0.001, and 52 +/- 16 beats/min vs. 81 +/- 14 beats/min, p < 0.001). The relative changes in stroke volume and cardiac output during submaximal exercise were lower in patients with HFpEF versus control subjects (ratio exercise/rest: 0.99 +/- 0.34 vs. 1.25 +/- 0.47, p = 0.04, and 1.36 +/- 0.45 vs. 2.13 +/- 0.72, p < 0.001). The nTTPF decreased during exercise in control subjects but increased in patients with HFpEF (-0.03 +/- 12 s vs. +0.07 +/- 0.11 s; p = 0.005). The VVC decreased on exercise in control subjects but was unchanged in patients with HFpEF (-0.01 +/- 0.15 vs. -0.25 +/- 0.19; p < 0.001).
CONCLUSIONS: Patients with HFpEF have reduced cardiac energetic reserve that may underlie marked dynamic slowing of LV active relaxation and abnormal VVC during exercise.

Entities:  

Mesh:

Year:  2009        PMID: 19628114     DOI: 10.1016/j.jacc.2009.05.012

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  99 in total

Review 1.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

2.  Myocardial Energetics in Heart Failure With Preserved Ejection Fraction.

Authors:  Omar F AbouEzzeddine; Bradley J Kemp; Barry A Borlaug; Brian P Mullan; Atta Behfar; Sorin V Pislaru; Marat Fudim; Margaret M Redfield; Panithaya Chareonthaitawee
Journal:  Circ Heart Fail       Date:  2019-10-15       Impact factor: 8.790

3.  Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction.

Authors:  Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Garvan C Kane; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

Review 4.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

Review 5.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 6.  Novel therapeutic targets for the treatment of heart failure.

Authors:  Juan Tamargo; José López-Sendón
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 7.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

8.  [New therapy concepts for heart failure with preserved ejection fraction].

Authors:  C Tschöpe; B Pieske
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

9.  Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.

Authors:  Muaz M Abudiab; Margaret M Redfield; Vojtech Melenovsky; Thomas P Olson; David A Kass; Bruce D Johnson; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2013-02-20       Impact factor: 15.534

10.  The pathophysiology of diastolic heart failure.

Authors:  Thanh Trung Phan; Michael Frenneaux
Journal:  F1000 Biol Rep       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.